Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California



 

Recent News and Articles on the Keywords: drug + hope + combination  Related to the article below (Last Update: 8/5/2008)


Oneindia
New HIV Drug Offers Hope For
Oneindia, India - Aug 4, 2008
Scientists at the University of New South Wales (UNSW) say that a drug to treat HIV infection offers new hope for millions of patients. ...

Calgary Herald
Mary-Kate Olsen?s Lawyer Speaks Out on Ledger Death
The Gossip Girls -
An autopsy showed the actor, 28, had prescriptions for pain, anxiety and sleep medications and the combination had killed him. ...
AssociatedPress
all 900 news articles »
Alzheimer's drug offers fresh hope
Financial Times, UK - Jul 29, 2008
Successful treatment might require a triple combination of drugs, to fight plaques and tangles and boost neurotransmitter activity, he said.
Influenza drug from BioCryst in clinical trials
The Kaleidoscope, AL - Aug 4, 2008
Researchers hope that this dosage of the drug will be well tolerated by the population, speed flu recovery and rapidly decrease the virus load in influenza ...
Safety Scares Hit Elan, Biogen And Schering
Forbes, NY - Aug 1, 2008
The drug was eventually allowed back onto the market with the stipulation that it not be given in combination with other drugs, after MS patients had ...ELN - OTC:SHRGY - BIIB
'Your whole world is turned upside down'
Galena Gazette, IL -
The individual drugs have been proven to slow down the disease. With the university study, doctors hope to find a combination that can eradicate it ...
Disease a threat to kitties here
Elk Valley Times, TN -
Findings from new research just released this past month show some signs of hope, the veterinarian said. A combination of two drugs ? atovaquone and ...

Eurweb.com
THE MO'KELLY REPORT: Where Rick Ross Meets Johnny Gill
Eurweb.com, CA -
Bob was exposed as a sick combination of CB4, Milli Vanilli and Malibu?s Most Wanted?all rolled into one disgusting fat body. A supposed gangster rapper was ...
A Practical "ABCDE" Approach to the Metabolic Syndrome
RedOrbit, TX -
Niacin has been shown to reduce secondary cardiovascular events in the Coronary Drug Project.77 In combination with a statin, the drug seems to slow ...
Nastech Pharmaceutical Company Inc. Q2 2008 Earnings Call Transcript
Seeking Alpha, NY -
Our platform technology has matured to a point that we can develop siRNA drug candidates against a variety of human diseases with the hope of beginning to ...MRNA
Source: Google News

Combination therapy for malaria in Africa: hype or hope? -
PB Bloland, M Ettling, S Meek - Bulletin of the World Health Organization, 2000 - SciELO Public Health
... Combination therapy for malaria in Africa: hype or hope? Peter B. Bloland, 1 Mary
Ettling, 2 & Sylvia Meek 3. The development of resistance to drugs poses one ...
-

From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis. -
S Yusuf - Am J Cardiol, 2002 - ncbi.nlm.nih.gov
... ca The Heart Outcomes Prevention Evaluation (HOPE) study conclusively ... more than
treatment with either drug alone in ... Val-HeFT) showed that the combination of an ...

Use of antipsychosis and adjunctive medications by an inner urban community psychiatric service -
NA Keks, K Altson, J Hope, N Krapivensky, C … - Australian and New Zealand Journal of Psychiatry, 1999 - Blackwell Synergy
... of patients are receiving combinations of antipsychotic ... (2004) Prescription of
psychotropic drugs to patients ... Tune, Jenny Babb, Edwina Brennan and Judy Hope. ...

Artemisinin-based combination therapies (ACTs): Best hope for malaria treatment but inaccessible to … -
TK Mutabingwa - Acta Tropica, 2005 - Elsevier
... Artemisinin-based combination therapies offer the best hope for adequate ... benefits
of slowing the emergence and spread of anti-malarial drug resistance and ...

Genomic signatures to guide the use of chemotherapeutics -
A Potti, HK Dressman, A Bild, RF Riedel, G Chan, R … - Nat Med, 2006 - nature.com
... Sayer 4 , Janiel Cragun 4 , Hope Cottrill 4 ... 1 . In addition, in several instances,
combination chemotherapy in ... respond, we combined in vitro drug response data ...

… the prevention of antimalarial drug resistance: Rationale for combination chemotherapy for malaria -
NJ White, PL Olliaro - Parasitology Today, 1996 - Elsevier
... Piero Olliaro discuss the rationale for combination chemotherapy ... While waiting for
new drugs with novel mecha ... to be discovered, developed and hope- fully deployed ...

Declining morbidity and mortality among patients with advanced human immunodeficiency virus …
FJ Palella Jr, KM Delaney, AC Moorman, MO Loveless … - N Engl J Med, 1998 - aids-clinical-care.highwire.org
... Therapy with combinations of these drugs, which inhibit ... Several offer significant
hope for patients and clinicians ... resistance profiles, even within drug classes ...

Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients … -
KD Miller, LI Chap, FA Holmes, MA Cobleigh, PK … - Journal of Clinical Oncology, 2005 - jco.ascopubs.org
... Reimann , Amy P. Sing , Virginia Langmuir , Hope S. Rugo ... 80%) was similar to the
combination therapy of ... in the capecitabine group required drug dose reduction ...

Better blood pressure control: how to combine drugs -
MJ Brown, JK Cruickshank, AF Dominiczak, GA … - Journal of Human Hypertension, 2003 - nature.com
... it is more evident when an ACE inhi-bitor is added to other antihypertensive drugs,
as in HOPE, 29 than when used as sole therapy. 33 Combination therapy may ...

Unexpected Serious Toxicity With Chemotherapy and Antiangiogenic Combinations: Time to Take Stock! -
GM Marx, CB Steer, P Harper, N Pavlakis, O Rixe, D … - Journal of Clinical Oncology, 2002 - jcojournal.org
... as one of a number of classes of new drugs giving hope to patients ... toxicity with
the specific angiogenesis inhibitor/chemotherapy combination of SU5416 ...

Source: Google Scholar

Drug Combination Fuels Hope for MS Fight

LONDON (AP) -- Four years ago, 28-year-old multiple sclerosis patient Karen Ayres was wheelchair-bound and paralyzed. "I was trapped in a body that wouldn't do anything," she says. Now, following an experimental drug treatment, she has regained mobility and is studying for a doctoral degree.

Ayres was one of 27 patients with aggressive MS who was treated in an open trial with a course of cancer-drug mitoxantrone and copaxone, which is used to treat relapsing MS.

Like Ayres, many of the other patients in the study experienced results so remarkable that some MS experts, while expressing caution, are now taking a second look at the preliminary experiment.

A three-year controlled study is being launched at 10 centers across the United Kingdom to further investigate the potential of the drug combination. The results of the initial trial, led by Dr Mike Boggild at the Walton Centre in Liverpool, will be published next month in the Journal of Neurology.

Mitoxantrone is an anti-cancer drug so powerful that it is potentially toxic and can only be used safely in the short term. So, Boggild and his colleagues combined its use with copaxone - a notoriously slow-acting drug.

"We decided to overlap the treatments because we wanted to give some time to copaxone to build up its effect," says Boggild.

What happened next was dramatic. "Patients who were just the worst of the worst did remarkably well," Boggild said.

"We think we've tapped into an unexpected synergy between the two drugs that gives you more than the sum of the parts," he says. With a few exceptions, Boggild says most of the patients treated with the drug combination are now essentially "trouble-free."

Though one patient developed acute leukemia - a known side effect to mitoxantrone treatment - Boggild says the majority of patients haven't had disease relapses.

Patients were first given a limited course of mitoxantrone, before being started on copaxone, usually a few months later. In Ayres' case, recovery was rapid. "From barely being able to wave my hand to walking out of the rehabilitation center took a few weeks," she says.

While the study has clearly generated some impressive results, many experts say more time is needed.

"It's a small study with no control group," says Dr Robyn Wolintz, co-director of the MS Center at Maimonedes Medical Center in New York. "They also gave different people different doses of mitoxantrone, and that's not standard," says Wolintz, explaining that changing the dosages and the frequency of the treatment makes it difficult to reproduce these results to verify the drugs' efficacy.

"We're talking about an early, small study," says David Harrison, of the MS Society in the United Kingdom. Though Harrison characterized the results as "encouraging," he believes it is necessary to conduct a large-scale comparative investigation to establish how the mitoxantrone-copaxone combination ranks against other known and potential drug cocktails.

Still, some experts believe Boggild and his colleagues have stumbled upon a valid hypothesis. "Single drugs are not what gets the job done," says Dr John Richert, vice-president of research department in the United States' National MS Society. "It really is likely that more and more combination therapies will be used."

For patients with particularly aggressive MS, the proposed treatment may provide some hope. "The people who could benefit from this have nothing else at their disposal," says Wolintz.

And unfortunately, medicine is far from an exact science. "Many physicians make their decisions based on incomplete data," says Richert. "Even though there's not sufficient data to make any kind of formal recommendation, there is enough data to say that it is reasonable to make this option available to physicians and their patients when they've weighed all the pros and cons of the situation."

For patients like Ayres, who still takes daily injections of copaxone, life without the treatment is unimaginable. "When I was lying in my hospital bed, not even able to twitch my toes, I was jealous of anyone who could walk," she told The Associated Press.

Despite the potential side effects, which include leukemia and cardiac problems, Ayres says the treatment was worth the risk. "I didn't have a lot of options," she says, "and to be completely normal now was worth everything that I went through."

Advocates Demand Funding for Pain Treatment

WASHINGTON (AP) -- Shawn Spriggs went through a slew of doctors and medicines before he found relief from the waves of muscular pain that shot through his body from muscular dystrophy.

A doctor who specialized in pain management dipped into her own pocket to buy him two $530 boxes of morphine lollipops made for cancer patients. Spriggs died of respiratory and heart failure in March, a 65-pound 20-year-old lying in his mother's arms in their Crestline, Ohio, home, a few suckers into the second box.

His mother, Kristi Spriggs, now has joined an emerging movement of pain sufferers, caretakers, scientists and others who want doctors to treat pain as its own disease and want government researchers to get more money to learn more about it.

In the last year, the American Pain Foundation has started mobilizing its members to relay their stories of living with constant pain. Kristi Spriggs said she has joined the cause as a way to grieve for Shawn.

Comedic legend Jerry Lewis, 80, has spoken on Capitol Hill about the relief he gets for chronic back pain from an implanted electric stimulator made by the pioneer of the pacemaker, Medtronic Inc. of Minneapolis.

As the U.S. population ages and medical advancements keep Americans living longer, chronic pain is becoming a more critical problem, said Dr. Edward Langston, chairman-elect of the American Medical Association board of trustees. An estimated 50 million to 75 million people live with chronic pain, defined as constant pain lasting at least three months.

Five years after it was introduced to little interest, proposed legislation now has the AMA's support to increase funding for pain research to the National Institutes of Health and create six pain research centers around the country.

"When you consider that a quarter of our population suffers from chronic pain, it is a burgeoning issue," said Langston, a family physician in Lafayette, Ind. "We believe this bill should be a significant priority."

But the proposal has languished for several reasons. The study of how pain works is relatively new, which has prevented money from flowing to developing new treatments, said Dr. Lawrence Tabak, co-chairman of an NIH consortium that coordinates pain research across the various institutes and centers.

With budget deficits holding total NIH funding at about $28 billion a year, Congress has not been willing to pay for a whole new program. Langston said the problem of pain has become profound enough that the NIH should adjust its funding priorities.

There are about six times more Americans living with chronic pain than with all kinds of cancer. The NIH has its own Cancer Institute, which received $4.8 billion in 2005, or about 20 times more than the $229 million that went to pain research.

Rep. Mike Rogers, R-Mich., whose brother's 20-year battle with serious back pain inspired him to propose the pain bill in 2001, said too many medical schools and residency programs push pain into the background, making it the subject of optional courses and Saturday electives.

"Doctors leave school as bright, caring, compassionate people without the skill-set to treat those with severe chronic pain," Rogers said.

Langston agrees that more training should be available. In 2003, the American Medical Association created a free continuing education program for doctors to learn what medical school didn't teach them about treating pain, and 84,000 doctors signed up in the first six months.

There are also cultural and societal barriers to pain management. Army Capt. Jonathan Pruden of Gainesville, Fla., who was severely injured by a roadside bomb in Iraq, told one of Rogers' congressional hearings about wounded soldiers who won't acknowledge their pain or refuse to take narcotics because of the stigma of possible addiction.

Pain-care advocates complain that the U.S. war on drugs, while catching some criminal drug distribution by a few doctors, has scared many more good ones away from prescribing narcotics to those with legitimate chronic pain.

The federal Drug Enforcement Administration disputes any chilling effect, citing a 40 percent rise in prescriptions of the opioid hydrocodone in the last five years. Langston said more research and training for doctors and drug enforcement agents will help regulators keep drugs off the streets and flowing to patients in need.

Only recently have scientists agreed that there's a science behind diagnosing and treating pain, Langston said. Modern theories of how pain is felt, over a system of nerve pathways through the spinal cord to a pain center in the brain, weren't developed until the 1960s and are still being perfected. Tabak said federal funding will start to flow now that the science of pain is maturing.

"We're now seeing developments in genomics and proteomics brought to bear on the management of pain," Tabak said, referring to mapping of human genes and proteins. "Five years ago, those words didn't even exist."

Patient voices are driving new interest in Congress. At Rogers' first hearing in 2001, one reporter and three observers showed up, the Lansing-area lawmaker said. A hearing last month drew about 150 people, including the staff of 52 lawmakers.

"The patients have a significant amount of power to make things change, and that's the momentum we've seen in the last year," said Will Rowe, executive director of the American Pain Foundation.

---

On the Net:

NIH pain information: http://painconsortium.nih.gov/

American Pain Foundation: http://www.painfoundation.org

Rep. Mike Rogers' proposed bill, H.R. 1020: http://thomas.loc.gov/

 
 
Google
Web www.iconocast.com

Search inside Iconocast for the keyword you have in mind.

Iconocast has collected more than 50,000 articles and press releases on health and science.

These are current and most up to date press releases on the subject you are searching.

We collect current health and science press releases daily from more than 5000 research and health institutes. Here is an example : The elderberry way to perfect skin

We believe if you do search inside Iconocast, you will get better results than searching the web alone.

 
 
ALL THE NEWS : News1 ; News2 ; News3 ; News4 ; News5 ; News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

Contact Iconocast

© 2003-07. ICONOCAST is a trademark of iconocast.com.